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1. Introduction
When providing medical 
care doctors often use a com-
bination of drugs. Prerequisites 
for this may be the presence of 
several illnesses in the patient 
(which is more typical for older 
people), as well as the inadequate 
efficacy or safety of monothera-
py. At the same time, according 
to research results, combined 
administration of drugs sharply 
increases the risk of side effects 
[1, 2]. Introduction of 2 drugs 
leads to adverse drug reactions 
(ADR) due to interactions be-
tween drugs in 6 % of patients, 
and the use of 5 drugs increases 
their frequency to 50 %. When 
taking 10 medicines, the risk of 
drug interactions reaches 100 % 
[3]. In patients who took more 
than 6 drugs, intergroup interac-
tions caused 59.1 % of all detect-
ed ADR [4].
Due to a significant increase 
in the use of medicines and their 
combinations, the correspond-
ing increase in the frequency of 
drug interactions was noted. The 
interaction of drugs implies a 
change in the effectiveness and 
safety of one of them while si-
multaneously or sequentially 
with another drug [5, 6]. The 
interaction of drugs, which leads 
to increased efficiency and safe-
ty of pharmacotherapy, under-
lies the rational combination of 
drugs. However, the interaction 
can lead to a decrease in the 
effectiveness of pharmacothera-
py, while talking about irrational 
combinations of drugs. And the 
bases of potentially dangerous 
combinations (PDC) are inter-
actions that reduce the safety 
of pharmacotherapy. PDC drugs 
are considered one of the seri-
ous clinical problems [7, 8]. They 
are considered as errors that can 
be prevented, because in the in-
structions on the use of drugs 
this is indicated. There are open 
online resources, in some coun-
tries/hospitals, there is an appro-
priate software that warns phy-
sicians about the possibility of 
dangerous interactions between 
drugs that are prescribed to patients [9]. However, doctors do 
not always use the indicated capabilities; therefore, it is rele-
vant to determine the frequency of cases of the administration 
of PDC drugs [10, 11]. This is necessary for further work on 
the prevention of such cases, as 
they are hazardous to the life and 
health of patients.
Aim of the research. To ana-
lyze the structure and prevalence 
of the appointments of potentially 
dangerous combinations of drugs 
in treating patients under inpa-
tient treatment for further opti-
mization of pharmacotherapy.
2. Methods
The study was conducted by 
continuous sampling and ret-
rospective analysis in the auto-
mated medical records (lists of 
medical appointments) of 69405 
patients who were under inpa-
tient treatment of 30 healthcare 
facilities in Zhytomyr region in 
2017 and received medication 
at the expense of the charity 
organization “Sickness fund of 
the Zhytomyr region” (SF) (pro-
totype of the regional health in-
surance fund). From the lists of 
appointment of patients to the 
electronic database information 
was provided on the diagnosis 
with an indication of the cipher 
by ICD-10, designated trade-
marks of medicinal products, 
which were provided by the SF, 
the name of the department. The 
program contained an electronic 
directory of medicines in the 
form of drug groups and indi- 
vidual medicines for trade and 
international non-proprietary na- 
mes (INNs), as well as a refer-
ence book of pairwise combina-
tions of medicines by INNs, with 
the simultaneous appointment 
of which a dangerous interaction 
is possible. As a source of data 
on hazardous interactions was 
used “State Form of Medicines”, 
issue 9 [12]. For automated mon-
itoring of the presence of PDC 
drugs, reporting forms were de-
veloped using the Microsoft Ac-
cess program.
In addition, in the first 
phase, cases of PDC were con-
firmed through the Drug In-
teraction Checker system of the 
online resource www.drugs.
com [13], harmonized with the 
FDA’s recommendations. Major 
combinations were selected for further analysis according to 
the levels of clinical significance (hazardous – potentially 
dangerous interactions between drugs: the risk of combined 
use of an ultrasound scanner exceeds the benefit for the 
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further work on their prevention.
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of the appointments of potentially dangerous combinations 
of drugs in the treatment of patients under inpatient treat-
ment for further optimization of pharmacotherapy.
Materials and methods. In the automated mode, the lists of 
medical appointments of patients who were under inpatient 
treatment of 30 health facilities of Zhytomyr region in 2017 
were monitored for the purpose of the simultaneous use of 
drugs, the interaction of which is dangerous. For further 
analysis by the levels of clinical significance using the Drug 
Interaction Checker system, the "Major" (hazardous) and 
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Internet resource www.drugs.com. The frequency of the ap-
pointments of dangerous combinations, their prevalence by 
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found that the average number of prescriptions per pa-
tient was 5.6±1.2 titles. In 1390 cases of treatment (2.0 % of 
69405) simultaneously prescribed medicines, the interaction 
of which could be dangerous. In the structure of dangerous 
combinations, 81.5 % is taken with the simultaneous ad-
ministration of drugs containing active substances ketorolac 
and pentoxifylline. The frequency of potentially dangerous 
appointments was greatest in the treatment of patients with 
diseases of the blood and blood-forming organs (D50-D89) – 
11.6 %, in diseases of the musculoskeletal system and con-
nective tissue (M00-M99) – 7.7 %, in diseases of the nervous 
system – 5.0 % of all cases of treatment.
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patient, therefore, in most cases it is necessary to avoid such 
combinations of drugs or to use drugs in minimal doses) 
and Moderate (significant interlaced interactions of medi-
um importance: such combinations require more rigorous 
clinical, laboratory and instrumental control of efficiency 
and safety).
Only the drugs purchased by the SF were monitored (with-
in the scope of the list, which included more than 800 trade 
names).
3. Results
As a result of the monitoring, 69405 electronic sheets of 
appointments of patients who received inpatient care in hospi-
tals in Zhytomyr region during 2017 determined that 389 INN 
drugs were used in general, the average number of medical 
appointments was 5.6±1.2 preparations per one the patient. 
There were 1390 cases of drug PDC appointments (2.0 % of 
the total number of treated patients). After checking through 
the Drug Interaction Checker system, the online resource 
www.drugs.com refers to the 1282 combinations (92.2 %) to the 
Major group, and to the Moderate group 108 (7.8 %) (Table 1).
Table 1
Detected by monitoring results of the appointment of dangerous 
combinations of drugs









Ketorolac Pentoxifyl-line 1133 81.5 Major
Ketorolac Acetylsalicyl-ic acid 70 5.0 Major
Ketorolac Warfarin 5 0.4 Major
Theophylline Pentoxifyl-line 60 4.3 Moderate
Gentamicin Furosemide 38 2.7 Major
Gentamicin Vancomycin 10 0.7 Moderate
Diphenhydr-
amine Metoprolol 36 2.6 Moderate
Warfarin Clopidogrel 22 1.6 Major
Warfarin Dipyrida-mole 2 0.1 Moderate
Verapamil Sotalol 7 0.5 Major
Verapamil Ivabradin 4 0.3 Major
Atorvastatin Clarithro-mycin 2 0.1 Major
Ivabradin Diltiazem 1 0.1 Major
Total 1390 100.0
The frequency of potentially dangerous appointments was 
greatest in the treatment of patients with diseases of the blood 
and blood-forming organs (D50-D89) – 11.6 %, in the second 
place (the first – in absolute numbers) PDC was prescribed for 
diseases of the musculoskeletal system and connective tissue 
(M00-M99) – 7.7 %, in the third – diseases of the nervous system 
(5.0 % of all cases of treatment) (Table 2).
According to the frequency of PDC appointments, drug 
profiles were dominated by the neurological profile – 7.7 %, 
traumatological – 3.7 %, and surgical – 2.5 % (Table 3).
Table 2
Frequency of appointments of potentially dangerous 
combinations of drugs for nosological classes by ICD-10









D50-D89: Diseases of the blood 
and blood-forming organs 190 22 11.6
M00-M99: Diseases of the musculo-
skeletal system and connective tissue 5689 439 7.7
G00-G99: Diseases of the nervous 
system 1921 96 5.0
S00-T98: Injury, poisoning and 
certain other consequences of 
external causes
3933 120 3.1
P00-P96: Certain conditions origi-
nating in the perinatal period 793 24 3.0
I00-I99: Diseases of the circulatory 
system 14239 398 2.8
E00-E90: Endocrine, nutritional 
and metabolic diseases 1204 30 2.5
L00-L99: Diseases of the skin and 
subcutaneous tissue 1339 22 1.6
K00-K93: Diseases of the digestive 
system 7606 92 1.2
A00-B99: Certain infectious and 
parasitic diseases 1118 13 1.2
C00-D48: Neoplasms 6630 57 0.9
Q00-Q99: Congenital malforma-
tions, deformations and chromo-
somal abnormalities
732 4 0.5
H60-H95: Diseases of the ear and 
mastoid process 404 2 0.5
O00-O99: Pregnancy, childbirth 
and the puerperium 5834 25 0.4
N00-N99: Diseases of the genito-
urinary system 5858 23 0.4
Other diseases 2571 8 0.3
H00-H59: Diseases of the eye and 
adnexaа 1219 2 0.2
J00-J99: Diseases of the respiratory 
system 8125 13 0.2
Total 69405 1390 2.0
Table 3
Frequency of appointments of potentially dangerous 





Number of PDC 
appointments Frequency, %
neurological 6359 487 7.7
traumatological 2698 99 3.7
surgical 14170 349 2.5
resuscitation 6661 138 2.1
therapeutical 19242 224 1.2
maternity 2935 28 1.0
gynaecological 4641 34 0.7
urological 1359 6 0.4
otolaryngologic 1486 5 0.3
pediatric 5037 13 0.3
ophthalmic 1113 2 0.2
infectious 3003 5 0.2
Other 701 0 0.0




According to the results of the study, was noted a low fre-
quency of appointments of drug combinations (only in 2.0 % of 
patients (1390 from 69405)), where the use of them may lead to 
dangerous interactions. The actual complications due to the ap-
pointments of these combinations have not been documented. 
The results we receive are much lower than the actual danger-
ous complications described by the authors with a frequency of 
6.2 % [1] and 14.6 % [14]. The relatively low PDC in our study 
was due to a significant sample size (69405 cases), which includ-
ed patients of different ages, and a small number of appoint-
ments per patient (5.6 drugs). This is significantly less than the 
result of 19.3 %, obtained by researchers through a retrospective 
analysis of 140349 hospitalizations [3]. In analyzing the PDC ap-
pointments in 200 patients over the age of 69 years [4], research-
ers report a result of over 75 % (patients received 7 drugs). The 
study [11] monitored the treatment of patients who prescribed 
more than 6 drugs, respectively, PDC were recorded in over 
54 % of the hospitalized patients. In the study [5], the average 
number of appointments was more than 10, so prescribed PDC 
were over 71 % of patients. The reason for the small number of 
PDC detected in our study is the limited availability of input data 
(only drugs purchased for the funds of the “Sickness fund”, for the 
treatment of the underlying disease and its complications) were 
taken into account, and the availability in medical institutions of 
doctors-experts in the “Sickness fund” carried out preliminary 
and current control over the rational use of drugs.
Among all the PDC found in our study, 81.5 % is a danger-
ous combination of drugs with active substances ketorolac and 
pentoxifylline, with the simultaneous administration of which 
significantly increases the risk of bleeding. This combination is 
most often prescribed for the provision of medical care in the 
departments of neurological, therapeutic, surgical profiles, in 
the treatment of patients with diseases of the musculoskeletal 
system and circulatory system. This indicates the need to in-
form doctors of different specialties about the dangers of the 
appointment of the combination, which will reduce the overall 
frequency of PDC appointments to 0.4 % of patients.
The conducted research confirmed the need for continuous 
monitoring of medical appointments regarding the presence 
of dangerous combinations and the introduction of a system 
for informing healthcare workers and the population about 
clinically significant drug interactions. This will increase the 
efficacy and safety of pharmacotherapy.
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